Reneo Pharmaceuticals (Reneo Pharmaceuticals) Inventory Turnover : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Reneo Pharmaceuticals Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Reneo Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Reneo Pharmaceuticals's Average Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Reneo Pharmaceuticals Inventory Turnover Historical Data

The historical data trend for Reneo Pharmaceuticals's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reneo Pharmaceuticals Inventory Turnover Chart

Reneo Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory Turnover

Reneo Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventory Turnover	Get a 7-Day Free Trial													-	-	-	-	-

Reneo Pharmaceuticals Inventory Turnover Calculation

Reneo Pharmaceuticals's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory Turnover (A: Dec. 2023 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2023 )	/ (	(Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Reneo Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

	Inventory Turnover (Q: Mar. 2024 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2024 )	/ (	(Total Inventories (Q: Dec. 2023 )	+	Total Inventories (Q: Mar. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Reneo Pharmaceuticals (NAS:RPHM) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Reneo Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Reneo Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	0
	=

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Reneo Pharmaceuticals Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Reneo Pharmaceuticals's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Reneo Pharmaceuticals (Reneo Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reneo Pharmaceuticals Inc (NAS:RPHM) » Definitions » Inventory Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

18575 Jamboree Road, Suite 275-S, Irvine, CA, USA, 92612

Website

https://www.reneopharma.com

Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

Executives

Ashley Hall	officer: Chief Development Officer	C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Niall O'donnell	director	C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Michael Cruse	officer: Senior VP, Corporate Operation	C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jennifer Lam	officer: VP of Finance & Administration	C/O RENEO PHARMACEUTICALS, INC., 18575 JAMBOREE ROAD, SUITE 275-S, IRVINE CA 92612
Paul W. Hoelscher	director	1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Vineet R. Jindal	officer: Chief Financial Officer	C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Gregory J. Flesher	director, officer: President and CEO	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Bali Muralidhar	director	C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Wendy S. Johnson	officer: Chief Development Officer	800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Rivervest Venture Fund Iii (ohio), L.p.	10 percent owner	11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Rivervest Venture Fund Iii, L.p.	10 percent owner	7733 FORSYTH BOULEVARD, ST. LOUIS MO 63105
Stacey Denenberg Seltzer	director	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106